Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Kyverna Therapeutics, Inc. roe for the quarter ending 2026-06-30 was -92.20%, a change of -6.13% year-over-year.
Kyverna Therapeutics, Inc. roe for the quarter ending 2026-03-31 was -79.97%, a change of -15.05% year-over-year.
Kyverna Therapeutics, Inc. roe for the quarter ending 2025-12-31 was -69.45%, a change of -21.63% year-over-year.
Kyverna Therapeutics, Inc. roe for the quarter ending 2025-09-30 was -105.95%, a change of -69.40% year-over-year.
Kyverna Therapeutics, Inc. roe for fiscal 2025 was -69.45%, a change of -21.63% from fiscal 2024.
Kyverna Therapeutics, Inc. roe for fiscal 2024 was -47.82%, a 110.41% decline from fiscal 2023.
Kyverna Therapeutics, Inc. roe for fiscal 2023 was 459.44%.